Health Condition 1: G439- Migraine, unspecified
Conditions
Interventions
Intervention1: Capsule Shaqiqa: Two capsules (500mg each) orally twice a day to be taken with water for 12 weeks
Control Intervention1: Tablet Divalproate: 250 mg (body weight 30kg) OR 850mg (body wei
Sponsors
Central Council for Research in Unani Medicine CCRUM New Delhi
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients of either gender in the age group 18- 65 years 2. Primary diagnosis of Migraine without aura by ICHD-3 beta as follows: A. At least five attacks fulfilling criteria Bâ??D. B. Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated). C. Headache has at least two of the following four characteristics: Unilateral location Pulsating quality Moderate or severe pain intensity Aggravation by or causing avoidance ofroutine physical activity (e.g. walking or climbing stairs). D. During headache at least one of the following: 1. Nausea and/or vomiting. 2. Photophobia and phonophobia. E. Not better accounted for by another ICHD-3diagnosis.
Exclusion criteria
Exclusion criteria: 1. Known case of any structural brain abnormalities 2. Known case of Ocular disease 3. History of Ischaemic stroke 4. Any disease involving sinus e.g. Rhinosinusitis 5. Systemic illness requiring long term treatment 6. Known cases of Chronic kidney & liver disease 7. Known cases of Psychiatric illness 8. Difficulty distinguishing migraine headache from other headaches 9. Known cases of Epilepsy and other neurological disorders 10. History of alcohol and drug abuse. 11. Pregnancy & lactation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in signs and symptoms of Shaqiqa (Migraine)Timepoint: The patients will be assessed clinically at baseline and at every two weeks till the completion of the trial i.e. upto 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Haematological and biochemical assessment for safety assessmentTimepoint: At baseline and at every two weeks till the completion of the trial i.e. upto 12 weeks | — |
Countries
India
Contacts
Public ContactDr Pradeep Kumar
Central Council for Research in Unani Medicine (CCRUM)
Outcome results
None listed